BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, Mohraz M, Mardani M, Fattahi MR, Poustchi H. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016;16:e40959. [PMID: 27799966 DOI: 10.5812/hepatmon.guideline] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Behzadifar M, Gorji HA, Bragazzi NL. The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and meta-analysis. Arch Virol 2018;163:1131-40. [DOI: 10.1007/s00705-018-3767-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
2 Karimi-Sari H, Hosseini MA, Nikjoo N, Bagheri Baghdasht MS, Alavian SM. Patient-reported outcomes of sleep, mood and quality of life after treatment of chronic hepatitis C infection using direct-acting antiviral agents. Clin Microbiol Infect 2020;26:1093.e5-8. [PMID: 32353413 DOI: 10.1016/j.cmi.2020.04.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ranjbar Kermani F, Mousavi Hosseini K, Amini Kafi-abad S, Maghsudlu M, Sharifi Z, Mansournia MA, Alavian SM. Update on Transmission Modes of Hepatitis C Virus Among Volunteer Iranian Blood Donors: Analysis of a Matched Case-Control Study by Penalized Conditional Logistic Regression. Hepat Mon 2018;In Press. [DOI: 10.5812/hepatmon.69395] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mirzazadeh A, Hosseini-hooshyar S, Shahesmaeili A, Sharafi H, Shafiei M, Zarei J, Mousavian G, Tavakoli F, Ghalekhani N, Shokoohi M, Khezri M, Mehmandoost S, Shojaei MR, Karamouzian M, Briceno A, Morris MD, Alavian SM, Haghdoost A, Sharifi H, Page KA. An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study. International Journal of Drug Policy 2022;102:103580. [DOI: 10.1016/j.drugpo.2022.103580] [Reference Citation Analysis]
5 Alavian SM, Sharafi H. Update on Recommendations for the Clinical Management of Hepatitis C in Iran 2017. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.63956] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
6 Alavian SM, Sharafi H. Comment on 'Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study'. Eur J Gastroenterol Hepatol 2018;30:807-8. [PMID: 29847527 DOI: 10.1097/MEG.0000000000001124] [Reference Citation Analysis]
7 Moghimbeygi M, Alavian SM. Eradication of hepatitis C virus infection in thalassemia patients in Iran using various treatment strategies. J Virus Erad 2020;6:100006. [PMID: 33251024 DOI: 10.1016/j.jve.2020.100006] [Reference Citation Analysis]
8 Mohazzab-torabi S, Dolatimehr F, Sharafi H, Safi-abadi M, Rezaee-zavareh MS, Bayatpour E, Karimi-sari H, Alavian SM. Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic Review. Hepat Mon 2018;In Press. [DOI: 10.5812/hepatmon.82971] [Reference Citation Analysis]
9 Sharafi H, Alavian SH, Behnava B, Saeid Rezaee-Zavareh M, Nikbin M, Alavian SM. Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study. Caspian J Intern Med 2020;11:41-6. [PMID: 32042385 DOI: 10.22088/cjim.11.1.41] [Reference Citation Analysis]
10 Behzadifar M, Azari S, Gorji HA, Martini M, Bragazzi NL. The hepatitis C virus in Iran: health policy, historical, ethical issues and future challenges. J Prev Med Hyg 2020;61:E109-18. [PMID: 32490276 DOI: 10.15167/2421-4248/jpmh2020.61.1.1438] [Reference Citation Analysis]
11 Merat S, Sharifi AH, Haj-sheykholeslami A, Poustchi H, Fattahi B, Nateghi-baygi A, Alavian SM, Malekzadeh R. The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3. Hepat Mon 2016;17. [DOI: 10.5812/hepatmon.44564] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sharafi H, Poustchi H, Azimian F, Tamadoni B, Ramezani R, Gouya MM, Sheikh M, Hashemi F, Tashakorian M, Alasvand R, Alavian SM, Merat S. Performance of a rapid diagnostic test for screening of hepatitis C in a real-life prison setting. J Clin Virol 2019;113:20-3. [PMID: 30825832 DOI: 10.1016/j.jcv.2019.02.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
13 Hasanshahi Z, Hashempour A, Ghasabi F, Moayedi J, Musavi Z, Dehghani B, Sharafi H, Joulaei H. First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients. BMC Gastroenterol 2021;21:443. [PMID: 34819046 DOI: 10.1186/s12876-021-01988-y] [Reference Citation Analysis]
14 Ghanaat K, Sharafi H, Alavian SM. The Efficacy and Safety of Sofosbuvir/Daclatasvir Fixed-Dose Combination in Iranian Hemodialysis Patients with Hepatitis C Virus Infection. Nephro-Urol Mon 2021;13. [DOI: 10.5812/numonthly.114049] [Reference Citation Analysis]
15 Pouri AA, Ghojazadeh M, Pourasghari B, Baiaz B, Soghra Hamzavi F, Somi MH. Seroepidemiology and risk factors of hepatitis C virus infection in East Azerbaijan, Iran: a population-based Azar Cohort study. Caspian J Intern Med 2019;10:326-31. [PMID: 31558996 DOI: 10.22088/cjim.10.3.326] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol 2017; 9(33): 1239-1252 [PMID: 29312527 DOI: 10.4254/wjh.v9.i33.1239] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
17 Rezaee-zavareh MS, Hesamizadeh K, Sharafi H, Alavian SM. Treatment of Hepatitis C Infection with Direct-Acting Antiviral Agents in Liver-Transplant Patients: A Systematic Review and Meta-Analysis. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.12324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
18 Saeedi R, Mojebi-Mogharar A, Sandhu SK, Dubland JA, Ford JA, Yousefi M, Pudek M, Holmes DT, Erb SR, Peter Kwan W, Kendler DL, Yoshida EM. Lamivudine, Entecavir, or Tenofovir Treatment of Hepatitis B Infection: Effects on Calcium, Phosphate, FGF23 and Indicators of Bone Metabolism. Ann Hepatol 2017;16:207-14. [PMID: 28233741 DOI: 10.5604/16652681.1231577] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
19 Ahmed HR, Waly NGFM, Abd El-Baky RM, Yahia R, Hetta HF, Elsayed AM, Ibrahem RA. Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C. PLoS One 2021;16:e0249770. [PMID: 33857212 DOI: 10.1371/journal.pone.0249770] [Reference Citation Analysis]
20 Jamalidoust M, Shafaati M, Kalani M, Zare M, Ziyeayan M. MicroRNA let-7b inhibits hepatitis C virus and induces apoptosis in human hepatoma cells. Mol Biol Rep 2021. [PMID: 34807376 DOI: 10.1007/s11033-021-06955-0] [Reference Citation Analysis]
21 Dolatimehr F, Khosravi MH, Rezaee-zavareh MS, Alavian SM. Prevalence of occult HCV infection in hemodialysis and kidney-transplanted patients: a systematic review. Future Virology 2017;12:315-22. [DOI: 10.2217/fvl-2016-0138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Ziaee M, Hajihosseini M. Hepatitis Awareness Bus: A Model for Finding Unknown Hepatitis B and C Infections. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.11719] [Reference Citation Analysis]
23 Jordan AE, Perlman DC, Cleland CM, Wyka K, Schackman BR, Nash D. Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation. J Clin Virol 2020;124:104285. [PMID: 32007842 DOI: 10.1016/j.jcv.2020.104285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Tang S, Peng ZG, Li YH, Zhang X, Fan TY, Jiang JD, Wang YX, Song DQ. Synthesis and biological evaluation of tricyclic matrinic derivatives as a class of novel anti-HCV agents. Chem Cent J 2017;11:94. [PMID: 29086870 DOI: 10.1186/s13065-017-0327-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
25 Almazrou SH, Alsubki LA, Alsaigh NA, Aldhubaib WH, Ghazwani SM. Assessing the Quality of Clinical Practice Guidelines in the Middle East and North Africa (MENA) Region: A Systematic Review. J Multidiscip Healthc 2021;14:297-309. [PMID: 33603389 DOI: 10.2147/JMDH.S284689] [Reference Citation Analysis]
26 Sharafi H, Nikbin M, Alavian SH, Behnava B, Alavian SM. Efficacy and Safety of Generic Sofosbuvir/Ledipasvir Fixed-Dose Combination in Iranian Patients with Chronic Hepatitis C Virus Infection. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.12216] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
27 Taherkhani R, Farshadpour F. Lurking epidemic of hepatitis C virus infection in Iran: A call to action. World J Hepatol 2017; 9(24): 1040-1042 [PMID: 28932350 DOI: 10.4254/wjh.v9.i24.1040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
28 Sharafi H, Alavian SM. Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem? World J Hepatol 2018; 10(9): 543-548 [PMID: 30310532 DOI: 10.4254/wjh.v10.i9.543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
29 Cuypers L, Thijssen M, Shakibzadeh A, Deboutte W, Sarvari J, Sabahi F, Ravanshad M, Pourkarim MR. Signature of natural resistance in NS3 protease revealed by deep sequencing of HCV strains circulating in Iran. Infect Genet Evol 2019;75:103966. [PMID: 31323326 DOI: 10.1016/j.meegid.2019.103966] [Reference Citation Analysis]
30 Hashempour T, Dehghani B, Mousavi Z, Yahaghi M, Hasanshahi Z, Moayedi J, Akbari T, Davarpanah MA. Evaluating Drug Resistant Mutations to HCV NS3 Protease Inhibitors in Iranian Naïve Patients. Int J Pept Res Ther 2020;26:1699-710. [DOI: 10.1007/s10989-019-09957-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
31 Alavian SM, Rezaee-Zavareh MS. Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis. Hepat Mon 2016;16:e41077. [PMID: 27826322 DOI: 10.5812/hepatmon.41077] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
32 Miri SM, Sharafi H, Pouryasin A, Behnava B, Keshvari M, Salimi S, Karimi Elizee P, Alavian SM. The Role of Polymorphisms Near IFNL3 Gene as Predictors of Residual HCV RNA in Buffy Coat after Successful Antiviral Therapy. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.46539] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
33 Sharafi H, Behnava B, Azizi-Saraji A, Namvar A, Anvar A, Salimi S, Alavian SM. Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders. Virol J 2021;18:199. [PMID: 34620204 DOI: 10.1186/s12985-021-01659-0] [Reference Citation Analysis]
34 Sharafi H, Ghalamkari S, Hassanshahi A, Alavian SM. Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank. Microb Drug Resist 2019;25:1072-9. [PMID: 31021305 DOI: 10.1089/mdr.2018.0358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Miri SM, Sharafi H, Salimi S, Bokharaei-salim F, Behnava B, Keshvari M, Karimi Elizee P, Keyvani H, Alavian SM. Assessment of Hepatitis C Virus RNA in Peripheral Blood Mononuclear Cells as a Predictor of Response to Pegylated-Interferon and Ribavirin: A Cohort Study. Iran Red Crescent Med J 2017;19. [DOI: 10.5812/ircmj.46578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
36 Hesamizadeh K, Tavakoli A, Nikbin M. Peg-interferon Plus Ribavirin Combination Therapy in HCV Mono-infected and HCV/HIV Co-infected Patients in Iran. Med J Islam Repub Iran 2019;33:63. [PMID: 31456987 DOI: 10.34171/mjiri.33.63] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Merat S; SD1000 Research Team. SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. Clin Infect Dis 2020;70:2206-12. [PMID: 31504303 DOI: 10.1093/cid/ciz628] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
38 Ramezani A, Baesi K, Banifazl M, Mohraz M, Khorvash F, Yaran M, Tabarsi P, Dalirrooyfard AH, Motevalli F, Bavand A, Aghakhani A. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population. Clin Res Hepatol Gastroenterol 2019;43:594-602. [PMID: 31080115 DOI: 10.1016/j.clinre.2019.01.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
39 Khosravi A, Karimi-Sari H, Abedi-Andani M, Behnava B, Namvar A, Anvar A, Alavian SM. Acute changes in cardiac function by direct acting antiviral therapy for hepatitis C-infected patients with thalassemia. J Med Virol 2019;91:419-27. [PMID: 30204230 DOI: 10.1002/jmv.25314] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
40 Hesamizadeh K, Alavian SM, Najafi Tireh Shabankareh A, Sharafi H. Molecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A NS5B Phylogenetic Analysis with Systematic Review. Hepat Mon 2016;16:e42938. [PMID: 28123445 DOI: 10.5812/hepatmon.42938] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
41 Dolatimehr F, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM, Behnava B, Gholami-Fesharaki M, Sharafi H. Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis. Daru 2017;25:11. [PMID: 28427463 DOI: 10.1186/s40199-017-0177-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
42 Sarvari J, Dowran R, Hosseini SY, Fattahi MR, Erfani N. Association of PD-1 gene with outcome of hepatitis C virus infection. EXCLI J 2018;17:935-44. [PMID: 30564072 DOI: 10.17179/excli2018-1394] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
43 Habibi N, Nassiri-toosi M, Sharafi H, Alavian SM, Shams-ghahfarokhi M, Razzaghi-abyaneh M. Aflatoxin B 1 exposure and the risk of hepatocellular carcinoma in Iranian carriers of viral hepatitis B and C. Toxin Reviews 2019;38:234-9. [DOI: 10.1080/15569543.2018.1446027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
44 Karimi-Sari H, Bayatpoor ME, Alavian SM. Awareness Campaign in (bio)Medical Students in Iran: a model for increasing the knowledge regarding hepatitis B and C. Clin Microbiol Infect 2017;23:418-9. [PMID: 27956270 DOI: 10.1016/j.cmi.2016.11.022] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
45 Mirminachi B, Mohammadi Z, Merat S, Neishabouri A, Sharifi AH, Alavian SH, Poustchi H, Malekzadeh R. Update on the Prevalence of Hepatitis C Virus Infection Among Iranian General Population: A Systematic Review and Meta-Analysis. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.42291] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
46 Rezaee-Zavareh MS, Alavian SM. Letter: the efficacy of interferon-free regimens in HCV-related Child C cirrhosis needs careful interpretation. Aliment Pharmacol Ther 2017;46:76. [PMID: 28589589 DOI: 10.1111/apt.14083] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]